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INTRODUCTION 
The demand for more patient compliant dosage forms is 
increasing tremendously from the last two decades. As a result, 
the demand for their technologies is been increasing day by 
day. Due to the high development cost of a new drug entity, the 
pharmaceutical companies are focusing on the development of 
newer drug delivery systems for the existing drug with an 
improved efficacy and bioavailability together with reduced 
dosing frequency to minimize side effects [1].  
Maximum therapeutically active substances are present in the 
form of tablet, capsule, and pill or powder dosage forms for 
oral administration. These dosage forms are to be swallowed so 
that the pharmaceutically active substance can be absorbed via 
the gastrointestinal tract [2]. Some time the administration of 
tablets and capsules with a glass of water become inconvenient 
or impractical for some patients (e.g. patients with 
tuberculosis). However, oral dosage forms are difficult to 
administer in unconscious & non-cooperative patients. Many 
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pediatric and geriatric patients are unwilling to take these solid 
preparations due to fear of choking [3]. It has been found that 
approximately 25–30 % of the population finds it difficult to 
swallow an oral dosage form [4]. This disorder is also 
associated with number of medical conditions including Stroke, 
Parkinson‟s disease, head and neck radiation therapy and other 
neurological disorders including Cerebral Palsy. 
Immediate Release Drug Delivery System (IRDDS) has 
acquired an important position in the market by overcoming 
previously encountered administration problem and 
contributing in extension of patient life [1]. IRDDS has the 
unique property of rapidly disintegrating or dispersing and 
releasing the drugs as soon as they come in contact with the 
saliva, thus obviating the requirement of water during 
administration. The IRDDS usually disintegrates in the oral 
cavity within 15 seconds to 3 minutes. A major component of 
success in IRDDS is good taste.  
 
BIOPHARMACEUTICS CLASSIFICATION SYSTEM 
The Biopharmaceutics Classification System (BCS) was 
developed by a collaboration of academic, industrial and 
government scientists in order to provide guidelines for the 
development of oral dosage forms. The basic principle behind 
the classification system is that the absorption of immediate-
release dosage forms, orally administered drugs is driven by 
two properties viz. the solubility of the drug in the 
gastrointestinal tract and the permeability of the drug across the 
intestinal epithelial cell barrier. Proper in vitro surrogates for 
these two properties should allow prediction of a drug‟s 
absorption in vivo from in vitro assays [4]. The interest in this 
classification system stems largely from its application in early 
drug development and then in the management of product 
change through its life cycle. In early drug development, 
knowledge of the class of a particular drug is an important 
factor influencing the decision to continue or stop its 
development. Obviously a low solubility/low permeability drug 
will never be presented as an orally administered product and 
will probably encounter serious formulation difficulties. A 
company desiring to produce an oral dosage form will wish to 
limit its development to those molecules that are highly 
permeable. Increasingly, these considerations are incorporated 
from the very earliest phases, with the concept of property-
based design being used in combinatorial chemistry to target 
production of compounds showing optimal properties. In 
future, the experts predict an increasing shift from the in vitro 
cell-line screening models to absorption studies occurring 
predominately „in computro’, as computer models are 
developed to link molecular motives to absorption properties 
5
. 
The BCS guidance recommends a strategy for identifying 
expendable clinical bioequivalence tests and also recommends 
a class of immediate-release solid oral dosage forms for which 
bioequivalence may be assessed based on in vitro dissolution 
tests in order to improve the efficiency of drug development 
and the review process [5].  
According to the BCS, drug substances are classified as 
follows: 
Class I - High Permeability, High Solubility 
Class II - High Permeability, Low Solubility 
Class III - Low Permeability, High Solubility 
Class IV - Low Permeability, Low Solubility 
Currently, only Class I (highly soluble and highly permeable) 
drugs are eligible for a biowaiver. This policy is based on 
research showing systemic exposure to a drug, which is 
proportional to its rate and extent of absorption, is in turn 
related to its solubility and permeability, especially when the 
rate of dissolution is rapid in relation to gastric emptying. 
There is currently an ongoing exchange of ideas regarding the 
idea that Class III (high-solubility, low-permeability) 
compounds should also be eligible for a biowaiver.  
 
The underlying principle is that, once a compound is in 
solution, its systemic bioavailability is then dependent only on 
its permeability. If comparable solubilities and rates of 
dissolution in two different formulations can be revealed, the 
bioavailability will be comparable. Permeability is based on the 
chemical structure of a compound. Thus, a compound that has 
low permeability (Class III) will also have a lower permeability 
in different formulations. On the other hand, a compound with 
low permeability is not going to have even lower permeability 
in a different formulation. Absorption Systems is an active 
participant in this dialogue, with the FDA and members of the 
pharmaceutical industry, to extend eligibility for biowaivers 
beyond Class I to include Class III compounds
 
[5]. 
 
IRDDS TECHNOLOGY REVIEW 
The concept of IRDDS emerged with intent to provide patients 
with more convenient means of medication. These rapidly 
disintegrating and dissolving solid dosage forms release the 
drug as soon as they come in contact with the saliva, thus 
bypassing the need of water during drug administration – an 
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aspect that makes the dosage form highly attractive for the 
patient groups such as children and the elderly.  
Immediate Release Tablet (IRT) offer several advantages over 
other dosage forms such as effervescent tablets, dry syrups, 
chewing gums, or chewable tablets, which are commonly used 
to enhance patient acquiescence. Administering effervescent 
tablets or granules and dry syrups involve unavoidable 
preparation that includes intake of water. Elderly patients 
cannot chew large pieces of gum or tablets and occasionally 
experience the bitter or objectionable taste of the drug in the 
dosage form if the taste masking coating ruptures during 
mastication. 
 
Additional advantages of IRT: 
IRT are easy to administer and handle thus leads to better 
compliance, particularly who can not swallow such as elderly, 
stroke victims, bed ridden patients, patients affected by renal 
failure, who refuse to swallow such as pediatric, geriatric and 
psychiatric patients [6,7]. It provides rapid drug absorption due 
to pregastric absorption of drug from the mouth, pharynx and 
oesophagus as saliva passes down which may produce rapid 
onset of action [6] and it can result in improved bioavailability, 
as a result of reduced dosage, improved clinical act through a 
reduction of superfluous effects [8]. IRT improves safety by 
avoiding the risk of suffocation or choking due to physical 
obstructions during oral administration of conventional solid 
dosage form
 
[9]. Superior taste masking capability and good 
palatability helps to change the basic views of awareness of 
medication as “bitter pill” particularly in children. It also 
provides new industrial opportunity like product promotion, 
patent expansion, life cycle management, and product 
differentiations
 
[8]. It is suitable for administrations and patient 
compliance for disabled, for travelers and busy people who do 
not always have access to water. It has the ability to provide 
advantages of liquid medications in the form of solid 
preparation and conveniences of administration and accurate 
dosing as compared to liquids. 
 
Chronological development in IRT manufacturing 
technology: 
To make certain the tablet‟s fast dissolving feature, water must 
quickly egress into the tablet environment to cause rapid 
disintegration and instantaneous dissolution of the tablet. 
Maximizing the absorbent structure of the tablet matrix and 
incorporating an appropriate disintegrating agents or highly 
water soluble excipient in the tablet formulation are the basic 
approaches used in current fast dissolving tablet technologies 
[3, 10, 11]. Basically, the major function disintegrant is to 
oppose the effectiveness of the tablet binder and the material 
forces that act under compression to form the tablet. The 
mechanism by which tablet is broken down into smaller 
particles and then produces a homogeneous suspension or 
solution is based on capillary action, high swellability of 
disintegrants and chemical reaction (release of gases)
 
[11]. 
 
Different technologies have been employed for the formulation 
of IRT so far and each technique has a different system, and the 
resulting fast dissolving or fast disintegrating dosage form 
varies on various grounds like mechanical strength of final 
product, drug and dosage form stability, mouth feel, taste, 
dissolution rate of the formulation in saliva, swallowability, 
rate of absorption from the saliva and overall bioavailability. 
These technologies require specialized equipments and process. 
The various technologies  
 
 Freeze drying / lyophilization: 
Freeze drying is the process in which water is sublimed from 
the product after it is frozen. This technique creates an 
amorphous porous structure that can dissolve rapidly. The 
active drug is dissolved or dispersed in an aqueous solution of a 
carrier/polymer. The mixture is dosed by weight and poured in 
the wells of the preformed blister packs. The trays holding the 
blister packs are passed through liquid nitrogen freezing tunnel 
to freeze the drug solution or dispersion. Then the frozen blister 
packs are placed in refrigerated cabinets to continue the freeze-
drying. After freeze-drying the aluminium foil backing is 
applied on a blister-sealing machine. Finally the blisters are 
packaged and shipped.  
 
Sublimation: 
The key to rapid disintegration for IRT is the presence of a 
porous organization in the tablet matrix. Conventional 
compressed tablets that contain highly water-soluble 
ingredients often dissolve rapidly because of low porosity of 
the matrix. Hence to generate porous matrix, volatile 
ingredients are used that are later subjected to a process of 
sublimation.  
According to Heinemann et al., Knitsch et al., inert solid 
ingredients that display high volatility (e.g., ammonium 
bicarbonate, ammonium carbonate, benzoic acid, camphor, 
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naphthalene, urea, and urethane) were compressed along with 
other excipient into a tablet. The volatile material was then 
removed by sublimation, leaving behind a porous matrix. 
Solvents such as cyclohexane and benzene were also suggested 
for the generation of porosity in the matrix [12-14]. 
Koizumi et al. applied sublimation technology to manufacture 
tablets that rapidly dissolve in saliva using Mannitol as matrix 
former, and camphor as sublimating agent. The tablets were 
dissolved in 10-20 s and displayed satisfactory handling 
properties
 
[15].  
 
Spray drying: 
Spray drying is used in pharmaceutical industries to produce 
highly porous powders. The processing solvent is evaporated 
rapidly by spray drying, which renders the product highly 
porous and thus can be used in developing IRT.  In this 
technique, gelatin can be used as supporting agent and as 
matrix, mannitol as bulking agent and sodium starch glycolate 
or cross carmellose or crosspovidone are used as 
superdisintegrants. Tablets manufactured from the spray-dried 
powder have been reported to disintegrate in less than 20 
seconds in aqueous medium
 
[16].  
 
Mass extrusion: 
This expertise involves softening the active blend using the 
solvent mixture of water-soluble polyethylene glycol and 
methanol and subsequent eviction of softened mass through the 
extruder or syringe to get a cylinder of the product into even 
segments using heated blade to form tablets. The dried cylinder 
can also be used to coat granules for bitter drugs and thereby 
accomplish taste masking. 
 
Moulding: 
Moulding technique employs water-soluble ingredients so that 
the tablet dissolves completely and rapidly. The active 
ingredients usually are absorbed through the mucosal layer of 
the mouth. Following are the different moulding techniques. 
 
Compression moulding: 
It involves moistening the powder blend with a hydroalcoholic 
solvent followed by pressing it into mould plates to form a 
wetted mass (compression moulding). The solvent is then 
removed by air-drying. Such tablets are less compact than 
compressed tablets and posses a porous arrangement that 
hastens dissolution. 
 Heat moulding: 
This process uses an agar solution as binder and blister 
packaging well as mould to manufacture a tablet. The process 
involves preparing a suspension containing the preparation, 
agar, and sugar (e.g., mannitol or lactose), followed by pouring 
the suspension into the blister packaging well, solidifying the 
agar solution at room temperature to form a jelly, and finally 
drying under vacuum at approximately 30° C.   
 
No vacuum lyophilization: 
Another process used is called no vacuum lyophilization, 
which involves the evaporation of a solvent from a drug 
solution or suspension at standard pressure.  
Moulded tablets disintegrate more quickly and offer improved 
taste. These properties are enhanced when tablets with porous 
structures are produced or when components that are physically 
modified by the moulding process are used. Compared with 
lyophilization, tablets produced by the moulding technique are 
easier to adjust to industrial scale. Unfortunately, moulded 
tablets typically do not posses great mechanical strength. 
Erosion and breakage of the moulded tablets often occur during 
tablet handling and when blister packets were opened.  
 
Cotton candy process: 
The cotton candy process is also known as the “candy floss” 
process. An IRT is formed using a candy floss or shear form 
matrix, known as “floss”, the matrix is formed from 
saccharides or polysaccharides processed into amorphous floss, 
which is a fibrous material similar to the cotton candy fibers
 
[17]. The matrix is then cured or partially recrystallised to 
provide a compound with good flow properties and 
compressibility. The candy floss can then be milled and 
blended with active ingredients and compressed into IRT. 
However the high processing temperature limits the use of this 
technology to thermostable compounds only.  
 
 Direct compression: 
It is the simplest and most cost effective tablet manufacturing 
technique which can now be applied to preparation of IRT 
because of the availability of improved excipient especially 
superdisintegrants & sugar based excipient. 
 
Superdisintegrants: 
In many orally disintegrating tablet technologies based on 
direct compression, the addition of superdisintegrants 
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predominantly affects the rate of disintegration and hence the 
dissolution. The presence of other formulation ingredients such 
as water-soluble excipient and effervescent agents further 
accelerate the process of disintegration.  
 
The introduction of so-called superdisintegrants and a better 
understanding of their properties have increased the popularity 
of IRDDS [18]. Focusing on the disintegrant concentration can 
optimize tablet disintegration time. Below critical disintegrant 
concentration, tablet disintegration time is inversely 
proportional to disintegrant concentration. However, above 
critical concentration level, disintegration time remains 
approximately constant or even increases [19]. 
 
Ethypharm (Saint-Cloud, France) has introduced a technology, 
which contains coated crystals of drug and microgranules along 
with disintegrants. In this technology, two types of 
disintegrants are used; a disintegrating agent (e.g. modified 
cellulose), which has a high swelling force, and a swelling 
agent (e.g. starch), which has a low swelling force [20]. 
Another concept for rapid disintegration is effervescent tablet. 
The concept of effervescence is a well-known formulation art 
utilized in several dosage forms. However, the current 
technology uses this concept in a modified fashion to achieve 
fast-disintegrating dosage forms
 
[21]. The microparticulates are 
prepared by a novel technique involving the dispersion of 
active ingredients into suitable polymer dispersion together 
with other excipient such as mannitol and magnesium oxide. 
Typical polymers include ethyl cellulose, methyl cellulose, and 
acrylate and methacrylic acid resins. The active material and 
mannitol are added to the polymeric dispersion under stirring, 
followed by the addition of magnesium oxide. Mannitol and 
magnesium oxide added to aid active ingredient release from 
the polymeric coating and are known as release promoter in 
current technology. This mixture is dried for one hour at 50°C, 
delumped, and dried for another hour at the same temperature. 
The material is then screened (#8 mesh) and dried for one hour 
at 60°C. The formed microparticles, effervescent agents and 
other excipient, including flavorants, colorants and lubricants 
are blended and compressed into tablets at 1.0-2.0 kp hardness
 
[21]. The tablets are fragile with in-vivo disintegration time of 
less than one minute. Because the tablets are very soft, they are 
packed into foil-foil blisters using a specially designed 
packaging system. In an attempt to improve the friability of 
these tablets, a novel method, known as particulate effervescent 
couple, is developed to prepare the effervescent mixture. In this 
method the organic acid crystals are coated using a 
stoichiometrically less amount of base material as compared to 
the acid. The particle size of the organic acid crystals is 
carefully chosen to be greater than the base material for 
uniform coating of base material onto the acid crystals. The 
coating process is initiated by the addition of a reaction 
originator, which in this case, purified water. The reaction is 
allowed to proceed only to an extent of completion of base 
coating on organic crystals. The required end-point for the 
reaction termination is determined by measuring carbon di 
oxide evolution. The resulting effervescent couple can be used 
in tablet preparation by mixing with polymer-coated active 
ingredient particulate material and other excipient such as 
sweeteners, flavorants and lubricants [22].However the major 
drawback of effervescent excipient is their hygroscopicity (i.e. 
the ability to absorb atmospheric moisture). Hence, their 
production requires control of humidity conditions and 
protection of the final product. This is reflected in the overall 
cost of the product.  
 
 Sugar based excipient: 
This is another approach to manufacture IRT by direct 
compression. The use of sugar based excipient especially 
bulking agents like dextrose, fructose, isomalt, lactilol, maltilol, 
maltose, mannitol, sorbitol, starch hydrolysate, polydextrose 
and xylitol, which display high aqueous solubility and 
sweetness, and hence impart taste masking property and a 
pleasing palatability.  
 
Most commercial IRTs have been developed using mannitol as 
the bulk excipient of choice. Mannitol is tremendously 
preferred over lactose because of its extremely low 
hygroscopicity, excellent chemical and physical compatibility, 
good compressibility and better sweetness. IRT formulators 
prefer to use a directly compressible mannitol, which enables 
the preparation of robust tablets that can withstand processing 
and transportation. Specially textured directly compressible, 
spray-dried, or granulated mannitol excipients have been 
designed to meet these needs. These excipient under defined 
manufacturing conditions gives a highly porous structure and 
friable exterior structure which helps in faster disintegration of 
IRT, they also provide a satisfactory mouth feel and so suitable 
for use in preparation of harder IRT by direct compression at 
low pressure.  
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CURRENT TRENDS IN IRDDS 
Though several technologies are available for the preparation 
of IRT or rapid disintegrating tablet, a few have reached 
commercial marketed products. FDA considers these rapidly 
dissolving tablets as a new dosage form [1]. Some patented 
technologies are described here.  
 
Zydis™ technology: 
Zydis™ is the first fast dissolving dosage form in the market. 
Using concept of Gregory et al. Scherer has patented the 
Zydis™ technology [23]. Zydis™, the best known of the fast 
dissolving/disintegrating tablet preparations. The tablet 
dissolves in the mouth within seconds after placement on the 
tongue. The Zydis™ product is made to dissolve on the tongue 
in 2 to 3 seconds. The Zydis™ formulation is also self-
preserving because the final water concentration in the freeze-
dried product is too low to allow microbial growth. This 
technology is based on the model that it is forming an open 
matrix network containing the active ingredients. These are 
freeze-dried products containing water soluble matrix material 
and drug, which is performed in blister pockets and freeze 
dried to remove the water by sublimation. The resultant 
structures are very porous in nature and rapidly disintegrate or 
dissolve upon contact with saliva. Zydis™ must be produced in 
blister packs with peelable backing foil, because the units are 
not strong enough to withstand being pushed through the 
backing foil of a conventional blister. The use of water as the 
medium ensures the formulation of porous dosage form. 
Preservatives may be added in apt concentration to prevent 
microbial growth in aqueous solutions (during manufacture). 
Suspending agents and pH-adjusting excipient may be added if 
necessary. Collapse protectants such as glycine prevent the 
shrinkage of the Zydis™ units and may be useful additives.  
This technology has certain limitations. A water insoluble drug 
can be incorporated up to 400 mg per tablet or less, on the other 
hand water soluble drug can be incorporated only up to 60 mg, 
because water soluble drug might form eutectic mixtures and 
not freeze adequately, hence the dose is limited to 60 mg. A 
lyophilized disk is so lightweight and fragile, that it is 
unsuitable for conventional blister packing. The use of matrix 
forming agents such as gelatin and sugar based excipients in 
the formulation could overcome this problem. Freeze-drying is 
a relatively expensive and time consuming process. Other 
drawbacks of freeze-drying disks include fragility and poor 
stability during storage under stressful conditions.  
Flash Tab™ technology: 
The FlashTab™ technology is yet another Mouth Dissolving 
Tablet formulation patented by Prographarm group. It utilizes 
most of the same additives as in conventional compressed 
tablets. A disintegrating agent and a swelling agent are used in 
combination with coated drug particles in this formulation to 
produce a tablet that disintegrates in mouth within one minute. 
This technology utilizes the conventional tabletting technology 
[24].  
 
OraSolv™ technology: 
It is CIMA lab‟s first fast-generation dissolving formulation. 
The tablets are prepared by direct compression technique at 
low compression force in order to minimize oral disintegration 
and dissolution time. The active medicament is taste masked 
and dispersed in saliva due to effervescent agent and provides a 
pleasant sensation of effervescence in mouth of the patient.  
OraSolv™ technology is an example of slightly effervescent 
tablet that rapidly dissolves in mouth [25]. This technology 
utilizes the effervescence materials and taste masked active 
ingredients and requires only conventional manufacturing 
process and equipment.  
OraSolv™ dosage forms have been developed, containing 
more than 1000 mg of active load and are capable of 
combinations of multiple active ingredients in a tablet. The 
main drawbacks of tablets produced by this technology are soft 
and friable and hence packaged using an integrated packaging 
line that uses a specially designed robotic pick and pack 
system.  
 
DuraSolv™ technology: 
DuraSolv™ is CIMA's second-generation fast-
dissolving/disintegrating tablet formulation. Produced in a 
fashion similar to OraSolv™, DuraSolv™ has much higher 
mechanical strength than its predecessor due to the use of 
higher compaction pressures during tabletting. DuraSolv™ 
tablets are prepared by using conventional tabletting equipment 
and have good rigidity (friability less than that 2%). The 
DuraSolv™ product is thus produced in a faster and more cost-
effective manner. DuraSolv™ is so durable that it can be 
packaged in traditional blister packaging, pouches or vials. 
One disadvantage of DuraSolv™ is that the technology is not 
compatible with larger doses of active ingredients, because the 
formulation is subjected to such high pressures on compaction. 
Unlike OraSolv™, the structural integrity of any taste masking 
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may be compromised with high drug doses. The drug powder 
coating in DuraSolv™ may become fractured during 
compaction, exposing the bitter-tasting drug to a patient's taste 
buds. Therefore, the technique is best suited for formulations 
including relatively small doses of active compound
 
[26]. 
 
WowTab™ technology: 
The WowTab™ fast-dissolving/disintegrating tablet 
formulation has been on the Japanese market for a number of 
years
 
[27]. Yamanouchi Pharmaceutical Co patents WowTab™ 
technology. The WOW in WowTab™ signifies the tablet is to 
be given “With Out Water”. WowTab™ is an intrabuccally 
soluble, compressed tablet consisting of granules made with 
saccharides of low and high mouldability. Mouldability is the 
capacity of the compound to be compressed. It has just recently 
been introduced into the U.S. The WowTab™ technology 
utilizes sugar and sugar like (e.g., mannitol) excipient. It uses a 
combination of low mouldability saccharides (rapid 
dissolution) and high mouldability saccharides (good binding 
property). The two different types of saccharides are combined 
to obtain a tablet formulation with adequate hardness and fast 
dissolution rate. Due to its significant hardness, the WowTab™ 
formulation is a bit more stable to the environment than the 
Zydis™ or OraSolv™. It is suitable for both conventional 
bottle and blister packaging. The taste masking technology 
utilized in the WowTab™ is proprietary, but claims to offer 
superior mouth feel due to the patented SMOOTHMELT 
action. The WowTab™ product dissolves quickly in 15 
seconds or less. 
 
FlashDose™ technology: 
Fuisz™ Technologies has three oral drug delivery systems that 
are related to fast dissolution. The first two generations of 
quick-dissolving tablets, Soft Chew™ and EZ Chew™, require 
some chewing. However, these paved the way for Fuisz's™ 
most recent development, FlashDose™. The FlashDose™ 
technology utilizes a unique spinning mechanism to produce a 
floss-like crystalline structure, much like cotton candy. This 
crystalline sugar can then incorporate the active drug and be 
compressed into a tablet. This procedure has been patented by 
Fuisz™ and is known as Shearform. The final product has a 
very high surface area for dissolution. It disperses and dissolves 
quickly once placed onto the tongue [28].  
Interestingly, by changing the temperature and other conditions 
during production, the characteristics of the product can be 
altered greatly. Instead of a floss-like material, small spheres of 
saccharides can be produced to carry the drug. The process of 
making microspheres has been patented by Fuisz™, and is 
known as CEFORM and serves as an alternative method of 
taste masking.  
 
OraQuick™ technology: 
The OraQuick™ fast dissolving tablet formulation utilizes a 
patented taste masking technology by K. V. Pharmaceuticals 
Company, who claim that its taste masking technology 
(Micromask) has superior mouth feel over taste masking 
alternatives. The taste masking process does not utilize solvents 
of any kind and therefore leads faster and more efficient 
production [29]. 
  
QuickDis™ technology: 
Lavipharm Laboratories Inc. (Lavipharm) has invented an ideal 
intraoral fast-dissolving drug delivery system, which satisfies 
the unmet needs of the market. The novel intraoral drug 
delivery system, trademarked QuickDis™, is Lavipharm‟s 
proprietary patented technology and is a thin, flexible, and 
quick-dissolving film. The film is placed on the top or the floor 
of the tongue. It is retained at the site of application and rapidly 
releases the active agent for local and or systemic absorption. 
This drug delivery system can be provided in various 
packaging configurations, ranging from unit-dose pouches to 
multiple-dose blister packages. 
The typical disintegration time, which is defined as the time at 
which the film begins to break when brought into contact with 
water, is only 5 to 10 seconds for the Quick-Dis™ film with a 
thickness of 2 mm. The dissolving time, which is defined as the 
time at which not less than 80% of the tested film is dissolved 
in aqueous media, is around 30 seconds for QuickDis™ film 
with a thickness of 2 mm. The typical release profile of an 
active ingredient exhibited by a QuickDis™ drug delivery 
system is 50% released within 30 seconds and 95% within 1 
minute. 
 
NanoCrystal ™ technology: 
For fast dissolving tablets, Elan's proprietary NanoCrystal™ 
technology can enable formulation and improve compound 
activity and final product characteristics. Decreasing particle 
size increases the surface area, which leads to an increase in 
dissolution rate. This can be accomplished predictably and 
efficiently using NanoCrystal™ technology. NanoCrystal 
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particles are small particles of drug substance, typically less 
than 1000 nanometers (nm) in diameter, which are produced by 
milling the drug substance using a proprietary wet milling 
technique NanoCrystal™ Fast dissolving technology provides 
for- pharmacokinetic benefits of orally administered 
nanoparticles (<2 microns) in the form of a rapidly 
disintegrating tablet matrix, product differentiation based upon 
a combination of proprietary and patent-protected technology 
elements and cost-effective manufacturing processes that 
utilize conventional, scalable unit operations. 
NanoCrystal colloidal dispersions of drug substance are 
combined with water- soluble GRAS (Generally Regarded As 
Safe) ingredients, filled into blisters, and lyophilized. The 
resultant wafers are remarkably robust; yet dissolve in very 
small quantities of water in seconds. This approach is 
especially attractive when working with highly potent or 
hazardous materials because it avoids manufacturing operations 
(e.g., granulation, blending, and tabletting) that generate large 
quantities of aerosolized powder and present much higher risk 
of exposure. The freeze-drying approach also enables small 
quantities of drug to be converted into IRT dosage forms 
because manufacturing losses are negligible. 
 
MeltEase™ technology: 
MeltEase™ Technology is a newer technology developed by 
Nutrition Formulators, which allows tablet dissolution in less 
than five seconds (average 400 mg tablet). This is the best 
mechanism available to ensure compliance and increase sales 
in two important markets, children and the elderly for many 
nutritional supplements at a very marginal development cost in 
specific formulations, including taste masking and sustained 
release on certain ingredients. 
 
CONCLUSION 
Besides delivering drug to the body, a drug delivery system 
aim to improve patient concordance and expediency, and IRTs 
are no exception. The introduction of IRDDS has solved some 
of the problem encountered in administration of drugs to the 
pediatric and geriatric patient, which constitutes a large portion 
of the world‟s population. The technologies described in this 
article demonstrate recent advances in formulation 
development and processing technologies need the effort to 
achieve more refined drug delivery system. Such products 
provide opportunity for the product of patent term of innovator. 
Due to this wide significance of IRT this drug delivery system 
may lead to better patient compliance and ultimate clinical 
output. Because of the availability of the technologies and 
strong patient demand, several products have already been 
commercialized and the market size for the IRT will surely 
enlarge further. Thus, looking at the advances and advantages 
in this therapeutic approach, the pharmaceutical formulator 
need not to restrict his choice in the development of 
conventional dosage forms but should also try to develop these 
IRDDS. Future might witness many more classes of drug 
developed in the form of IRT. 
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